Official Title Improving Physical Ability and Cellular Senescence Elimination in HIV (IPACE-HIV)

Purpose

The purpose of this study is to evaluate the safety and tolerability of dasatinib and quercetin (D+Q) and efficacy of this regimen in improving physical function outcomes in people with HIV (PWH) who are frail or prefrail.

Could this study be right for you?

• People living with HIV ≥50 years diagnosed with HIV 10 or more years ago
• Currently on combination antiretroviral therapy
• Currently virologically suppressed
• Must meet FFP criteria & have 4-meter gait speed in the range of .5-1.2 m/sec

Age Range

50 years and up

Official Title A randomized, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D)

Purpose

This study is testing a medicine called teplizumab to see if it can help people aged 18 to 25 who were recently diagnosed with Type 1 Diabetes (T1D). The goal is to find out if teplizumab can protect the cells in the body that make insulin, which helps control blood sugar.

People with T1D usually lose these insulin-producing cells over time, and this study wants to see if teplizumab can slow down or stop that process. Everyone in the study will continue using insulin as usual, but some will also get teplizumab (or a placebo, which has no medicine) through IV infusions.

Researchers hope this treatment will:

• Help the body keep making some of its own insulin

• Reduce the amount of insulin people need to take

• Improve blood sugar control

• Lower the risk of very low blood sugar levels

The study will last about 84 weeks (a little over a year and a half), and participants will have regular checkups and tests to see how well the medicine works and how safe it is.

Could this study be right for you?

• Must be diagnosed with Type 1 Diabetes in the past 2 months
• Must have had a positive test for at least one Type 1 Diabetes antibody
• For female participants of childbearing potential - must use a contraception method (or abstinence) 

Age Range

18 - 25 years

Official Title A Multicenter, Randomized, Double-blind, Sham-controlled study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals with Type II Diabetes (ReCET Study)

Purpose

To test the efficacy of a one-time non-surgical endoscopic procedure on improved glycemic control in patients with type 2 diabetes who are not on insulin. 

Could this study be right for you?

Participants are eligible to be included in the study if all of the following criteria apply:
1. 22-70 years of age, inclusive.
2. T2D diagnosis for at least 6 months.
3. HbA1c of 7.5-10.5%, inclusive, determined by central laboratory. If the individual is on four glucose-lowering medications, HbA1c should be between 7.5% and 9.0%.
4. BMI 27-40 kg/m2, inclusive.
5. On 2-4 non-insulin glucose lowering mediations or on monotherapy with either GLP-1, or GLP-1/GIP medications, with no changes in medication or dosing for at least 12 weeks prior to the baseline visit.
6. Individualized metabolic surgery (IMS) score ≤ 115.
7. Weight stability (defined as a < 5% change in body weight) for at least 12 weeks prior to the screening visit.
8. Agree not to donate blood during participation in the study.
9. Able to comply with study requirements and understand and sign the Informed Consent Form.
10. Women of childbearing potential must be not pregnant and using an acceptable method of contraception throughout the study.
11. Willing and able to comply with study visits and study tasks as required per protocol.

Age Range

22 - 70 years

Official Title Anti-inflammatory Activities of Vitamin C Supplementation on the Gut Barrier Function in Adults with Obesity

Purpose

This study is testing whether taking vitamin C can improve gut health and reduce inflammation in adults with obesity. We want to learn if vitamin C helps strengthen the gut lining (“gut barrier”), improve digestion, and support overall health.

Could this study be right for you?

• Body weight: Have overweight or obesity (BMI 30 or higher)

• Location: Able to come to The Ohio State University campus in Columbus, Ohio for study visits

• Diet: Willing to follow a low vitamin C diet during the study

• Health status: Generally healthy, without major chronic diseases other than obesity

• Other: Non-smoker, not pregnant or breastfeeding, not currently taking high-dose vitamin C supplements

Age Range

18 - 55 years

Official Title MIND-TNBC - Pilot study of a MIND diet intervention in women undergoing active treatment for triple negative breast cancer

Purpose

A research team at The Ohio State University in Columbus, OH, is recruiting participants for a remote study of diet and cognition among breast cancer patients.

Enrolled participants will be randomized to receive a personalized 12-week nutrition intervention for cognitive health with a registered dietitian-nutritionist or a 12-week general healthy lifestyle program and will complete all study visits remotely. Participants will be contacted 6 months after the intervention for data collection.

Could this study be right for you?

• Female
• Recently diagnosed with stage II-III triple-negative breast cancer
• Have just started, or soon will start systemic therapy (e.g. chemotherapy, targeted or endocrine therapies)
• English speaking

 

Age Range

40 - 65 years

Official Title A randomized, double-blind, placebo-controlled, parallel group, pilot study to evaluate the effect of a ketone ester on muscle and immune function in older men and women who are at risk for strength and mobility decline

Purpose

The purpose of this study is to measure the effect of 20 weeks of Ketone Ester consumption on a composite score of vigor-frailty in older adults who are at risk for mobility and strength decline and to investigate the effect of 20 weeks of Ketone Ester consumption on additional physical function measures, cognitive and immune function, muscle metabolism, safety, tolerability, gut microbiome, and quality of life in older adults who are at risk for mobility and strength decline. 

Could this study be right for you?

65 years of age or older

• living independently
• English speaking and able to understand study procedures and provide Informed Consent
• women must be post menopause
• ambulatory and able to pass the walk speed criteria at screening            
• minimum body weight of 50kgs (110 lbs.) at time of screening
• able to fast and abstain from alcohol, cannabis products and not exercise for 10 hours prior to study visits
• maintain current diet, exercise, medication and supplement use
• must not have a known allergy, intolerance, or sensitivity to any soy or milk protein
• must not be under active surveillance or treatment for cancer
• has not followed a ketogenic diet or used any ketone products within 30 days of screening or at anytime during the study period
• does not work night shifts or shifts that do not allow for a consistent meal schedule during the day
• does not take any immunosuppressive medications,  weight loss medications or supplements, chronic antibiotic usage or receiving chemotherapy
• must not adhere to any extreme dietary habits, including intermittent fasting, Atkins, vegan, high protein low carbohydrate
• must not be a heavy alcohol drinker (women 8 drinks or more per week; men 15 drinks or more per week)
• must not have uncontrolled elevated cholesterol upon results of screening laboratory results

Age Range

65 - 99 years

Official Title A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy

Purpose

This research is being done to see the effectiveness and safety of a new drug called BHV-7000 as a possible treatment for focal seizures for patients who are taking anti-seizure medications (ASMs) and still experiencing seizures. Refractory focal epilepsy is when someone continues to have focal seizures despite treatment with ASMs or other treatments.

People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and the study includes up to 7 in-person visits.

Could this study be right for you?

1. Experiencing at least 4 or more observable focal seizures per month

2. Taking at least 1 and up to 3 anti-seizure medications

3. Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 6 months

4. Between the ages of 18 to 75

Age Range

18 - 75 years

Official Title A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Purpose

In this research study a study drug named XEN1101 is being tested for the treatment of seizures. The main purpose of this study is to determine if XEN1101 can reduce the seizure frequency and if it is safe to use.  People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and includes up to 7 in-person visits.

Could this study be right for you?

1. Experiencing at least 3 PGTCS in an 8-week period

2. Have tried at least 2 anti-seizure medications without success

3. Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 12 months

4. 18 years old and up

Age Range

18 years and up

Official Title Sex Differences in Alcohol Use: Neural and Hormonal Influences

Purpose

The goal of the study is to gain a better understanding of how hormonal fluctuation across the female menstrual cycle impact brain activity and associated drinking behaviors.

Participation includes:
•    One orientation session (2 hours)
•    Three brain imaging (fMRI)/alcohol and saline administration sessions (7 hours each)
•    Six follow-up online surveys (30 mins each)
•    Two follow-up sessions (1 hour each)

The total time commitment of the study is 28 hours over the course of 21 months.

Could this study be right for you?

1. Age: 21–26 years old (must bring proof of age to Orientation, e.g., driver’s license or passport)
2. In good health, as confirmed by responses to the Screening Interview
3. No contraindications for fMRI (e.g., no metal in the body, as confirmed by MRI screening form)
4. Reports typical weekly alcohol consumption 
5. No current or past treatment for a drug or alcohol use disorder
6. Not currently pregnant, breastfeeding, or planning to become in the next 3 months (women only)
7. Regular menstrual cycles (women only)
8. No use  of hormonal contraception or plans to begin use within the next 3 months (women only)

Age Range

21 - 26 years

Official Title Identification of novel signatures of proximal changes in the severity of suicide risk states

Purpose

This study will examine how people experience mental health symptoms, distress, and suicidal thoughts in their daily lives, to identify signs that indicate that someone's suicide risk is getting worse or improving. We will recruit people who are at different levels of suicide risk.

You will be asked to complete a survey about your life experiences, mental health symptoms, suicide thoughts, and coping strategies. You will also be asked to complete short surveys on your phones several times a day for 28 days to understand how suicide risk changes over time, and you will be provided with mental health resources you can access if in crisis.

Could this study be right for you?

1. aged 18+
2. the ability to speak, read, and understand English well enough to participate in study procedures 
3. comfort with smartphone technology
4. are currently a U.S. resident
5. participants must endorse suicidal ideation in the past week
6. and/or endorse an suicide attempt, aborted attempt, or interrupted attempt within the past month

Age Range

18 - 100 years

Official Title Pain Sensitivity and Endogenous Pain Modulation in Autistic Adults (R21)

Purpose

The purpose of this project is to study how pain may differ in adults with or without autism. Our goal is to study whether or not pain is experienced of felt differently in autistic adults compared to non-autistic adults.

Participants will be screened by phone. After meeting the initial screening criteria, the study visit will be scheduled. Participants can expect one study visit lasting 2-3 hours with time built in for breaks.

Could this study be right for you?

• Not currently on any daily pain medications

Age Range

30 - 70 years

Official Title Examining the efficacy of a soft soy pretzel intervention in altering chronic inflammation and immune profiles in obese individuals

Purpose

The objective of this study is to evaluate if soy isoflavones, delivered via soft soy pretzels (SSP), can be an effective, feasible intervention for chronic inflammation.

 

All study visits will be at The Ohio State University Medical Center and the study will last 8 weeks and involve 7 clinic visits.

Could this study be right for you?

You may be eligible if you:

• Are a male between 18 and 49 years old
• Have a body mass index (BMI) less than 25 or greater than or equal to 30
• Are not allergic to soy or soy-containing products
• Are not actively trying to lose weight

Exclusion criteria: 

• Current or prior history of Type 2 diabetes mellitus as defined by ICD-10-CM E11
• Current or prior history of cancer (excluding non-melanoma skin cancers)
• History of blood clotting disorders or adverse events relating to blood draws
• Use of antibiotic regime lasting longer than one week within the last six months
• Strict veganism (no consumption of animal, fish, or egg products)
• Heavy alcohol consumption (defined as consumption of >14 drinks/week on average)
• Current or prior history of any condition that causes altered immunity such as chronic inflammatory disease, autoimmune disorders, cancer, anemia, and blood dyscrasias
• Regular usage of inflammation lowering medications which include but not limited to nonsteroidal anti-inflammatory drugs such as aspirin, ibuprofen, and naproxen, or anti-pyretic medications such as acetaminophen

 

Age Range

18 - 49 years